|
Feb 19
|
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
|
|
Feb 18
|
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
|
|
Feb 21
|
Devonian Announces the Results of its Annual General and Special Shareholders' Meeting, the Approval of Amendments to its Stock Option Plan, and Grant of Stock Options
|
|
Feb 20
|
Devonian Bolsters Intellectual Property With Issuance of U.S. Patent Covering a Method of Treatment of Inflammatory Bowel Disease
|
|
Dec 24
|
Devonian Health Group First Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.009 loss in 1Q 2023)
|
|
Dec 4
|
Devonian Bolsters Leadership Team and Aligns Strategy to Accelerate Clinical Development and Drive Revenue Growth and Commercial Success
|
|
Nov 8
|
Devonian Files Patent Cooperation Treaty (PCT) Application for Thykamine™ in Wound Healing
|